Last deal

$40M

Amount

Venture - Series Unknown

Stage

08.08.2011

Date

3

all rounds

$158.35M

Total amount

date founded

Financing round

General

About Company
Enobia Pharma develops therapies for serious genetic bone disorders.

Industry

Sector :

Subsector :

founded date

01.01.1997

Number of employees

Company Type

For Profit

Last funding type

Venture - Series Unknown

IPO status

Private

Description

The company specializes in developing treatments for genetic bone disorders that have no approved therapies available. Enobia's focus is on hypophosphatasia (HPP), a rare and potentially life-threatening disease that affects bone development. The company's products have shown promising results in clinical trials, and they are continuing to research and develop new therapies to improve the lives of patients with HPP and other genetic bone disorders. Enobia's mission is to provide effective treatments for these rare diseases and improve the quality of life for those affected by them.
Contacts

Contact Email

Phone number

Social url

Similar Companies
1000
Apicell Therapeutics

Apicell Therapeutics

Developer of gene therapies for the treatment of immunological diseases

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Gimhae-si, Gyeongsangnam-do, South Korea
Rocket Pharmaceuticals

Rocket Pharmaceuticals

Rocket Pharma is a clinical-stage biotech company developing gene therapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Location

Grand Cayman, Cayman Islands

total rounds

12

total raised

$891.06M
GeneVentiv Therapeutics

GeneVentiv Therapeutics

GeneVentiv Therapeutics is a pre-clinical gene therapy company focused on developing treatments for blood diseases and disorders.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Raleigh, NC, USA

total rounds

3

total raised

$3.95M
CommBio

CommBio

Developer of gene therapies for the treatment of multiple disease conditions

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Pudong, Shanghai, China
M&A Details
1

Acquired by

Alexion Pharmaceuticals

announced date

29.12.2011

Financials

Funding Rounds
5
3

Number of Funding Rounds

$158.35M

Money Raised

Their latest funding was raised on 08.08.2011. Their latest round Venture - Series Unknown

Date 
Funding Round 
Investors 
Money Raised 
Lead 
08.08.2011
$40M
01.04.2011
$15M
10.08.2009
4
$50M
Co-Investors
Investors
8
5

Number of lead investors

8

Number of investors

Investor 
Lead 
Round 
Partners 
No
Series A
Yes
Series B, Series C
Innova-Tech Consulting

Innova-Tech Consulting

Innova-Tech Consulting provides independent specialist audio visual and technology consulting services.

Sector

Technology Hardware and Equipment

Subsector

Electronic Office Equipment

Keywords

Consulting

count Of Investments

5

count Of Exists

2
T2C2 Capital

T2C2 Capital

T2C2 identifies and commercializes business opportunities in universities, research centers, and industry.

Sector

General Industrials

Subsector

Diversified Industrials

Keywords

Financial Services, Venture Capital, Finance

Location

Dorval, QC, Canada

count Of Investments

11

count Of Exists

6
OrbiMed

OrbiMed

OrbiMed is a healthcare-focused investment firm managing approximately $5 billion in assets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Venture Capital, Health Care

Location

New York, NY, USA

count Of Investments

559

count Of Exists

82
Jonathan Silverstein

Jonathan Silverstein

Jonathan Silverstein, JD, joined OrbiMed Advisors, LLC in 1998 to focus on private equity and structured transactions in small capitalization public biotechnology and medical device companies. Mr. Silverstein was a Director of Life Sciences in the Investment Banking Department at the Sumitomo Bank and an Associate at Hambro Resource Development. Mr. Silverstein has a JD and an MBA from the University of San Diego, and a BA in Economics from Denison University. Currently, Mr. Silverstein is the Chairman of Enobia Pharma, Inc., Cerapedics, Inc., and Gelesis, and he is a Director at superDimension, Ltd., Glaukos Corporation and Nxstage Medical, Inc. He has been a Director or observer in more than a dozen other companies, including: LifeCell Corporation, Given Imaging, Ltd., Cerexa, Inc. (sold to Forest Laboratories, Inc.), Peninsula Pharmaceuticals, Inc. (sold to Johnson & Johnson, Inc.), Predix Pharmaceuticals, Inc.(sold to Epix Pharmaceuticals, Inc.), Avanir Pharmaceuticals, Inc., Orthovita, Inc., Auxillium Pharmaceuticals, Inc., Bioenvision (sold to Genzyme Corporation), Adiana, Inc. (sold to Cytyc Corporation) and Adolor Corporation.

current job

OrbiMed
OrbiMed

People

Employee Profiles
15
Frank Wright

Frank Wright

Senior Vice President

Stephen Squinto

Stephen Squinto

Executive Vice President, Chief Global Operations Officer.

Jeff Mack

Jeff Mack

CFO

Leonard Bell

Leonard Bell

Vice-President, Global Nephrology Franchise. ,Board of Director

David Hallal

David Hallal

Executive Vice President and Chief Commercial Officer

Clare Carmichael

Clare Carmichael

Senior Vice President, Chief Human Resources Officer

Robert Heft

Robert Heft

CEO & President

Henric Bjarke

Henric Bjarke

Vice President, Global Metabolic Diseases Franchise.

Activity

Recent News
0